Search the Newsreel

Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?

In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic …

Boston Scientific (BSX) Stock Looks Cheap On Earnings And Fair Value

Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted …

Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses

Parnassus Investments, an investment management company, released the "Parnassus Core Equity Fund" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance …

Union Bancaire Privee UBP SA Sells 173,105 Shares of Boston Scientific Corporation $BSX

Union Bancaire Privee UBP SA significantly reduced its stake in Boston Scientific Corporation by selling 173,105 shares, retaining 62,129 shares valued at $2.6 million. Despite this, institutional investors collectively own 89.07% of the company, and insiders, including CEO Michael F. Mahoney, recently purchased over …

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these …

Here’s What Hurt Boston Scientific Corporation (BSX) in Q2

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve …

Boston Scientific Corporation $BSX Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd significantly increased its stake in Boston Scientific Corporation by 148.8% in Q2, acquiring 670,060 additional shares to reach a total of 1.12 million shares valued at $47.8 million. Insiders also showed confidence, with CEO Michael Mahoney purchasing 186,240 shares …

QRG Capital Management Inc. Buys 198,951 Shares of Boston Scientific Corporation $BSX

QRG Capital Management Inc. significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 121.5% in the second quarter, acquiring 198,951 additional shares and bringing its total holdings to 362,716 shares valued at $15.5 million. This comes amidst strong financial performance from Boston Scientific, …

Boston Scientific Corporation $BSX Shares Purchased by Fisher Funds Management LTD

Fisher Funds Management LTD significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.1% in the second quarter, bringing its total holding to approximately $43 million. This comes as institutional investors collectively own 89.07% of BSX. Boston Scientific recently reported strong quarterly revenue …

Brookstone Capital Management Sells 233,448 Shares of Boston Scientific Corporation $BSX

Brookstone Capital Management significantly reduced its stake in Boston Scientific, selling 233,448 shares and retaining a smaller position. Despite this sale, institutional investors still hold a large percentage of the company, and analysts maintain a "Moderate Buy" rating. Boston Scientific recently surpassed quarterly earnings …

Belo Sun Mining Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Boston Scientific Corp (BSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Boston Scientific Corp (BSX), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It also includes an analysis of moving averages and addresses frequently asked questions regarding technical ratings and moving …

Boston Scientific's CEO Bought $9M of His Own Stock

Boston Scientific's CEO, Michael Mahoney, purchased approximately $9 million of his company's stock, with two directors also buying shares and no 10b5-1 plan in place. Additionally, CoStar founder-CEO Andrew Florance bought about $2.5 million of his own stock. The article also notes that President …

Boston Scientific (BSX) SVP Emily Woodworth adds 2,930 shares in 401(k) rebalance

Emily Woodworth, SVP, Global Controller and CAO at Boston Scientific (BSX), acquired 2,930 shares of common stock at $51.19 per share through a 401(k) rebalance on August 11, 2026. This transaction increased her indirect 401(k) holdings to 2,930 shares, in addition to her 3,123 …

Bank of America Securities Reaffirms Their Buy Rating on Boston Scientific (BSX)

Boston Scientific (NYSE:BSX) Screens as a Decent Value with Strong Fundamentals

Northside Capital Management LLC Purchases 49,189 Shares of Boston Scientific Corporation $BSX

Northside Capital Management LLC significantly increased its stake in Boston Scientific Corporation by 44.2% in the second quarter, bringing its total holdings to 160,366 shares valued at $6.84 million. The medical equipment provider has a consensus "Moderate Buy" rating from analysts and recently reported …

How MiRus got $1.5B Boston Scientific investment for heart valve - Atlanta Business Chronicle

Marietta-based MiRus, led by Dr. Jay Yadav, has secured a $1.5 billion investment from Boston Scientific for its heart valve replacement technology. The company is pursuing FDA approval for its innovative heart valve, which utilizes a superalloy, driven by Yadav's personal motivation and past …

Boston Scientific Corporation $BSX Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB significantly reduced its stake in Boston Scientific Corporation, selling 91.4% of its shares in the second quarter. Despite this, institutional investors collectively own a substantial portion of the company, and insiders have made significant purchases. Boston Scientific …

BOSTON SCIENTIFIC AKTIE: AI-Analysen, Prognose & Kursziel

Boston Scientific (BSX) CFO adds 9,908 shares through discretionary 401(k) rebalancing

Jonathan Monson, EVP and CFO of Boston Scientific (BSX), acquired 9,908 shares of common stock on August 10, 2026, at $50.46 per share. This acquisition was a result of a discretionary rebalancing election within the company’s 401(k) Retirement Savings Plan. Following this transaction, Monson …

Boston Scientific Stock And 2 Low Volatility Picks For A Slower US Economy

Amidst growing concerns about a slower U.S. economy, this article identifies three low-volatility stocks—Boston Scientific (BSX), Aon (AON), and CorVel (CRVL)—that are well-positioned for resilience. Boston Scientific benefits from essential medical procedures, Aon from its risk management services, and CorVel from its debt-free status …

Handelsbanken Fonder AB Sells 1,002,628 Shares of Boston Scientific Corporation $BSX

Handelsbanken Fonder AB has reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 38.8%, selling over 1 million shares but retaining 1.58 million shares valued at $67.6 million. Despite this sale, institutional investors hold a significant 89.07% of the company, and analysts maintain a …

Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Boston Scientific Corporation (NYSE:BSX) has an average "Moderate Buy" rating from thirty-one brokerages, with an average 12-month price target of $71.62. The company recently exceeded quarterly earnings expectations with adjusted EPS of $0.86 and revenue of $5.44 billion, and announced a $5 billion share …

Boston Scientific Corp. stock outperforms competitors on strong trading day

Shares of Boston Scientific Corp. (BSX) rose 2.33% to $50.46 on Monday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average both decline. This marked the third consecutive day of gains for the stock.

Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?

David C. Habiger, a Director at Boston Scientific Corporation (NYSE:BSX), purchased 2,100 shares of Common Stock on August 5, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Shares purchased 2,100 Transaction value $99,939 Post-transaction shares (directly held) 17,160 Post-transaction value …

Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $10.1 million Shares purchased 208,359 Post-transaction shares (total) …

Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company

Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results

Boston Scientific (BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on September 10, 2026, with Mike Mahoney and Kenneth Stein, M.D., leading a Q&A session. The company will also webcast its third-quarter 2026 earnings call on October 28, 2026, hosted by Mike …

Boston Scientific (BSX) Nach Rückrufen Und Gekürzter Prognose Noch Günstig Oder Schon Eingepreist?

Boston Scientific Corporation $BSX Shares Purchased by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Boston Scientific Corporation by 9.9% in the second quarter, bringing its total holdings to 320,038 shares valued at $13.7 million. Boston Scientific exceeded Q2 earnings expectations with EPS of $0.86 and revenue of $5.44 billion, and authorized a …

Boston Scientific (NYSE: BSX) director adds 2,100 shares in open-market buy

Boston Scientific director David C. Habiger purchased 2,100 shares of common stock on August 5, 2026, in an open-market transaction. The shares were bought at a weighted average price of $47.589, with individual trade prices ranging from $47.21 to $47.98. Following this transaction, Habiger …